All In Biotech

Drug Trial Radar · NCT06407947

Study of CT071 Injection in High Risk Newly Diagnosed Multiple Myeloma

Exploratory Clinical Trial of the Safety and Efficacy of CT071 Injection in Patients With High Risk Newly Diagnosed Multiple Myeloma

Last checked: Nov 19, 2026Latest source record: Jun 12, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

10

Planned (sponsor's estimate)

Start

Jun 6, 2024

Primary completion

Jun 3, 2027

Study completion Jun 3, 2027

Sponsor

Lead sponsor
Shanghai Changzheng HospitalAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
CARsgen Therapeutics Co., Ltd.
First posted
May 9, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Early phase 1
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This trial is a single-arm, single-center, open-label clinical trial to evaluate the safety, efficacy, and metabolism kinetics of CT071 in patients with high-risk newly diagnosed multiple myeloma.

Conditions

  • Multiple Myeloma

Interventions

  • Chimeric antigen receptor modified T cells InfusionDrug

    chimeric antigen receptor T cells

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Adverse Events (AE) after CT071 infusionTime frame: From first dose of study drug administration to end of treatment (up to 24 months)
  2. Overall response rate (ORR)Time frame: From first dose of study drug administration to end of treatment (up to 24 months)
  3. Recommended Phase II Dose of CT071 in patients with high-risk newly diagnosed multiple myelomaTime frame: Assessed from the date of first dose of study treatment until 28 days

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Juan Du

    Shanghai, Shanghai Municipality, China · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.